company background image
C43 logo

Cosmo Pharmaceuticals DB:C43 Stock Report

Last Price

€67.50

Market Cap

€1.1b

7D

0%

1Y

20.5%

Updated

25 Mar, 2024

Data

Company Financials +

C43 Stock Overview

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide.

C43 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance1/6
Financial Health5/6
Dividends2/6

Cosmo Pharmaceuticals N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cosmo Pharmaceuticals
Historical stock prices
Current Share PriceCHF67.50
52 Week HighCHF70.50
52 Week LowCHF35.00
Beta1.2
1 Month Change0%
3 Month Change25.00%
1 Year Change20.54%
3 Year Change-8.78%
5 Year Change-13.79%
Change since IPO400.00%

Recent News & Updates

Recent updates

Shareholder Returns

C43DE PharmaceuticalsDE Market
7D0%3.0%1.3%
1Y20.5%-25.6%6.4%

Return vs Industry: C43 exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.

Return vs Market: C43 exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is C43's price volatile compared to industry and market?
C43 volatility
C43 Average Weekly Movement3.9%
Pharmaceuticals Industry Average Movement6.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: C43 has not had significant price volatility in the past 3 months.

Volatility Over Time: C43's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997319Alessandro Della Chahttps://www.cosmopharma.com

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers’ diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies.

Cosmo Pharmaceuticals N.V. Fundamentals Summary

How do Cosmo Pharmaceuticals's earnings and revenue compare to its market cap?
C43 fundamental statistics
Market cap€1.10b
Earnings (TTM)€1.15m
Revenue (TTM)€96.72m

956.4x

P/E Ratio

11.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C43 income statement (TTM)
Revenue€96.72m
Cost of Revenue€39.34m
Gross Profit€57.38m
Other Expenses€56.24m
Earnings€1.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)0.071
Gross Margin59.33%
Net Profit Margin1.19%
Debt/Equity Ratio0.1%

How did C43 perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

2,808%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.